Case management of the anemic patient: epoetin alfa--focus on iron supplementation

Epoetin alfa stimulates erythropoiesis, thus creating an increased need for iron, and virtually all patients with end-stage renal disease who receive this therapy will eventually require iron supplementation. This article describes the appropriate use of oral and intravenous iron supplementation, including patient assessment, education, and management.